Anemia in chronic heart failure: Etiology and treatment options

Current Opinion in Cardiology

Volumn 23, Issue 2, 2008, Pages 141-147

  Westenbrink, B Daan ^a   De Boer, Rudolf A ^a   Voors, Adriaan A ^a   Van Gilst, Wiek H ^a   Van Veldhuisen, Dirk J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anemia; Chronic heart failure; Erythropoietin

Indexed keywords

FERROUS SULFATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ANEMIA; BONE MARROW DEPRESSION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FLUID RETENTION; HEALTH HAZARD; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; IRON DEFICIENCY; KIDNEY FAILURE; MORTALITY; MULTICENTER STUDY; NONHUMAN; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SURVIVAL; WORLD HEALTH ORGANIZATION;

ANEMIA; CHRONIC DISEASE; ERYTHROPOIETIN, RECOMBINANT; HEART FAILURE; HUMANS;

EID: 40049100802     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3282f43025     Document Type: Review

References (43)

1. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998; 19 (Suppl P):9-16.
2. Hillege HL, Girbes AR, De Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102:203-210.
3. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113:671-678.
4. Van der Meer P, Voors AA, Lipsic E, et al. Erythropoietin in cardiovascular diseases. Eur Heart J 2004; 25:285-291.
5. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006; 113:2454-2461. Succinct but thorough and up-to-date review on the prevalence, etiology and treatment options of anemia in CHF.
6. Latado AL, Passos LC, Darze ES, Lopes AA. Comparison of the effect of anemia on in-hospital mortality in patients with versus without preserved left ventricular ejection fraction. Am J Cardiol 2006; 98:1631-1634.
7. Inglis SC, Stewart S, Papachan A, et al. Anaemia and renal function in heart failure due to idiopathic dilated cardiomyopathy. Eur J Heart Fail 2007; 9:384-390.
8. Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006; 27:1440-1446. This study revealed that the development of anemia in CHF should be considered a grave sign in all CHF patients.
9. Van der Meer P, Voors AA, Lipsic E, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004; 44:63-67.
10. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005; 26:2232-2237.
11. Westenbrink BD, Visser FW, Voors AA, et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2007; 28:166-171. This study explored the contribution of cardiorenal function parameters, fluid retention and relative EPO production on the occurrence of anemia in CHF. The most important finding of the study was that fluid retention already causes anemia in the absence of congestive symptoms, adding another component to the multifactorial nature of the disease.
12. Iversen PO, Woldbaek PR, Tonnessen T, Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 2002; 282:R166-R172.
13. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352:1011-1023.
14. Ferrucci L, Guralnik JM, Woodman RC, et al. Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med 2005; 118:1288.
15. Van der Harst P, Van der Steege G, De Boer RA, et al. Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol 2007; 49:1459-1464. This study revealed that leukocytes of patients with CHF display signs of increased aging (telomere attrition). Although it is still unknown whether this is the cause or the consequence of CHF, it does suggest accelerated aging in the hematopoietic stem cell. This might also contribute to the development of anemia in CHF.
16. Kissel CK, Lehmann R, Assmus B, et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol 2007; 49:2341-2349. Bone marrow endothelial progenitor cells and monocyte precursors from patients with ischemic cardiomyopathy were found to be functionally impaired, which also translated into their circulating progeny. Similar functional exhaustion might contribute to the development of anemia in CHF.
17. Androne AS, Katz SD, Lund L, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003; 107:226-229.
18. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006; 48:2485-2489. The first study on the etiology of anemia in CHF that explored iron stores in the bone marrow. The authors revealed markedly depleted iron stores, which might indicate an important role for iron-restricted erythropoiesis in CHF. Unfortunately no control group was included since diversion of iron stores might be a common trait in CHF, not necessarily causing anemia.
19. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37:1775-1780.
20. Palazzuoli A, Silverberg D, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006; 152:1096-1115.
21. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107:294-299.
22. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007; 49:753-762. First of three randomized double-blind placebo-controlled studies that evaluated the feasibility of darbepoetin alfa to correct anemia in CHF and its possible downstream effects on exercise tolerance.
23. Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al. Randomized, doubleblind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007; 28:2208-2216. Second of three randomized double-blind placebo-controlled studies that evaluated the feasibility of darbepoetin alfa for the correction of anemia in CHF. This study compared alternate dosing regimens and focused on clinical parameters including left ventricular function and quality of life in addition to exercise tolerance.
24. Ghali JK, Anand IS, Abraham WT, et al. Randomized, double-blind, placebo-controlled trial to assess the impact of darbepoetin alfa treatment on exercise tolerance in anemic patients with symptomatic heart failure: results from STAMINA-HeFT [abstract]. Circulation 2006; 114:II_571. Third and largest of three randomized double-blind placebo-controlled studies that evaluated the feasibility of darbepoetin alfa for the correction of anemia in CHF. Similar to the two latter studies, but comprised over 300 patients. A significant, hemoglobin-dependent increase in exercise tolerance was seen in addition to a tantalizing trend towards a reduction in cardiovascular events.
25. Van Veldhuisen DJ, McMurray JJ. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomized outcome trial. Eur J Heart Fail 2007; 9:110-112.
26. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071-2084.
27. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-2098.
28. Steinbrook R. Erythropoietin, the FDA, and oncology. N Engl J Med 2007; 356:2448-2451.
29. Pfeffer MA. An ongoing study of anemia correction in chronic kidney disease. N Engl J Med 2007; 356:959-961.
30. Sato T, Maekawa T, Watanabe S, et al. Erythroid progenitors differentiate and mature in response to endogenous erythropoietin. J Clin Invest 2000; 106: 263-270.
31. Lipsic E, Schoemaker RG, Van der Meer P, et al. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006; 48:2161-2167. Comprehensive, thorough and up-to-date review on the protective effects of EPO in ischemic heart disease.
32. Lipsic E, Van der Meer P, Voors AA, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006; 20:135-141. First human safety and feasibility study of a single intravenous bolus of EPO during a primary percutaneous coronary intervention for a first acute myocardial infarction. Not only was EPO safe and well tolerated, but it also increased the numbers of circulating endothelial progenitor cells.
33. Van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005; 46:125-133.
34. Satoh K, Kagaya Y, Nakano M, et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006; 113:1442-1450. This study convincingly showed that the myocardial EPO receptor is crucial for the endogenous adaptation to cardiomyocyte hypertrophy.
35. Hamed S, Barshack I, Luboshits G, et al. Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J 2006; 27:1876-1883.
36. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther 2005; 19:33-40.
37. Li L, Takemura G, Li Y, et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006; 113:535-543.
38. Li Y, Takemura G, Okada H, et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 2006; 71:684-694.
39. Westenbrink BD, Lipsic E, Van der Meer P, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007; 28:2018-2027. This study elucidates the mechanism of EPO-induced neovascularization in experimental CHF, revealing a crucial role for bone marrow-derived endothelial progenitor cells and concomitant myocardial upregulation of angiogenic factors.
40. Lipsic E, Westenbrink BD, Van der Meer P, et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing hematocrit. Eur J Heart Fail 2007 [Epub ahead of print]. This study revealed that the beneficial effects of EPO on cardiac function can be induced with doses that do not affect hematocrit, thereby averting the potentially negative effects of unrestricted elevation of hematocrit.
41. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006; 48:1225-1227. This study shows that intravenous iron might result in correction of anemia, signifying the fact that we should not neglect other treatable causes of anemia in CHF.
42. Sullivan JL. Long-term risks of increased use of intravenous iron. Lancet 2007; 370:481-482.
43. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, et al. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Card Fail 2007; 13:14-17.